A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 2, 2009, Pages 175-180

  Horti, József ^a   Widmark, Anders ^b   Stenzl, Arnulf ^c   Federico, Miriam H ^d   Abratt, Raymond P ^e   Sanders, Nick ^f   Pover, Gillian M ^f   Bodrogi, István ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f ASTRAZENECA   (United Kingdom)

Author keywords

Combination; Docetaxel; Hormone refractory prostate cancer; Prednisolone; Vandetanib

Indexed keywords

DOCETAXEL; PLACEBO; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN; VANDETANIB; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CALCIUM BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONSTIPATION; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DUODENAL ULCER BLEEDING; DYSGEUSIA; DYSPNEA; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INCIDENCE; INSOMNIA; LACRIMATION; LARGE INTESTINE PERFORATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PHOTOSENSITIZATION; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN EXFOLIATION; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; PIPERIDINES; PREDNISOLONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUINAZOLINES; TAXOIDS; TREATMENT OUTCOME;

EID: 66249113517     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0588     Document Type: Article

References (30)

1. Ryan AJ, Wedge SR. ZD6474 a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer 2005;92 (Suppl 1) :S6. (Pubitemid 40897411)
2. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645.
3. Herbst RS, Heymach JV, O'Reilly MS, et al. Vandetanib (ZD6474) : An orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Exp Opin Invest Drugs 2007;16:239. (Pubitemid 46206638)
4. Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401. (Pubitemid 24058195)
5. Bok RA, Halabi S, Fei DT, et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: A cancer and leukemia group B study. Cancer Res 2001;61:2533. (Pubitemid 32685834)
6. George DJ, Halabi S, Shepard TF, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001;7:1932. (Pubitemid 32994827)
7. Di Lorenzo G, Tortora G, D'Armiento FP, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen independence in human prostate cancer. Clin Cancer Res 2002;8:3438. (Pubitemid 35340719)
8. Marks RA, Zhang S, Montironi R, et al. Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: A fluorescence in situ hybridization and immunohistochemical analysis. Prostate 2008;68:919.
9. Schlomm T, Kirstein P, Iwers L, et al. Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res 2007;13:6579. (Pubitemid 350206791)
10. Guerin O, Formento P, LoN C, et al. Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol 2008;134:51. (Pubitemid 350060684)
11. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502. (Pubitemid 39315317)
12. Heymach JV, Johnson BE, Prager D, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol 2007;25:4270. (Pubitemid 47548567)
13. Rubinstein LV, Korn EL, Freidlin B, et al. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 2005;23:7199. (Pubitemid 46260307)
14. Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT Investigators. J Clin Oncol 2007;25:669. (Pubitemid 350002922)
15. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513. (Pubitemid 39315318)
16. Gross M, Higano C, Pantuck A, et al. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer 2007;7:142. (Pubitemid 47244883)
17. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al. Prostatespecific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007;25: 3965. (Pubitemid 47477275)
18. Collette L, Burzykowski T, Carroll KJ, et al. Is prostatespecific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. J Clin Oncol 2005;23:6139. (Pubitemid 46300232)
19. Petrylak DP, Ankerst DP, Jiang CS, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006;98:516. (Pubitemid 43898814)
20. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: Prediction, detection, and monitoring. Nat Rev Cancer 2008;8:268.
21. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148.
22. Steinbild S, Mross K, Frost A, et al. A clinical phase II study with sorafenib in patients with progressive hormonerefractory prostate cancer: A study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer 2007;97:1480. (Pubitemid 350175850)
23. Ryan CJ, Stadler WM, Roth B, et al. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs 2007;25:445. (Pubitemid 47222908)
24. Chi KN, Ellard SL, Hotte SJ, et al. A phase II study of sorafenib in patients with chemonaive castration-resistant prostate cancer. Ann Oncol 2008;19:746.
25. Small EJ, Fontana J, Tannir N, et al. A phase II trial of gefitinib in patients with nonmetastatic hormone-refractory prostate cancer. BJU Int 2007;100:765. (Pubitemid 47360196)
26. Boer K, Lang I, Llombart-Cussac A, et al. Vandetanib with docetaxel as second-line treatment for advanced breast cancer: A double-blind, placebo controlled, randomized phase II study. Presented at the 30th Annual San Antonio Breast Cancer Symposium, in San Antonio, Texas, December 13-16, 2007, as Abstract 6081.
27. Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005;16:1391. (Pubitemid 41158486)
28. Tamura T, Minami H, Yamada Y, et al. A Phase I doseescalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 2006;1:1002. (Pubitemid 47181370)
29. Drevs J, Siegert P, Medinger M, et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007;25:3045. (Pubitemid 47218051)
30. Wu S, Chen JJ, Kudelka A, et al. Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and meta-analysis. Lancet Oncol 2008;9: 117.